Shares of Aeterna Zentaris (AEZS +13.2%) pop after being initiated with a Buy at Roth Capital...

|By:, SA News Editor

Shares of Aeterna Zentaris (AEZS +13.2%) pop after being initiated with a Buy at Roth Capital with a price target of $1.75, more than double its current valuation. Roth cites optimism over its endometrial cancer candidate, AEZS-108, which plans to begin Phase III testing before the end of the year, the potential for its AEZS-130, an Adult Growth Hormone Deficiency diagnostic that the company is preparing for a New Drug Application.